Megestrol and Exercise in Treating Patients With Cancer-Related Weight Loss

Sponsor
Northwestern University (Other)
Overall Status
Completed
CT.gov ID
NCT00004912
Collaborator
National Cancer Institute (NCI) (NIH)
6
46

Study Details

Study Description

Brief Summary

RATIONALE: Megestrol helps improve appetite. Exercise may decrease cancer-related fatigue, improve strength, and build up lost muscle tissue. Exercise plus megestrol may be effective treatment for cancer-related weight loss.

PURPOSE: Phase II trial to study the effectiveness of megestrol plus exercise to improve appetite, increase strength, gain lean body tissue, and decrease fatigue in patients who have cancer-related weight loss.

Condition or Disease Intervention/Treatment Phase
  • Drug: megestrol acetate
  • Procedure: physical therapy
Phase 2

Detailed Description

OBJECTIVES: I. Determine the effect of megestrol and progressive resistance training on lean body mass, total body weight, functional capacity, appetite, and fatigue in patients with weight loss due to advanced malignancy.

OUTLINE: This is a multicenter study. Patients receive oral megestrol once daily. Patients also begin progressive resistance training 3 days a week. Treatment/exercise continues for 12 weeks in the absence of unacceptable toxicity or progressive weight loss (greater than 5 pounds or 5% or more over first 4 study weeks).

PROJECTED ACCRUAL: A total of 46 patients will be accrued for this study within 1 year.

Study Design

Study Type:
Interventional
Primary Purpose:
Supportive Care
Official Title:
Phase II Trial of Progressive Resistance Training With Megestrol Acetate for the Treatment of Cancer-Related Weight Loss
Study Start Date :
Jan 1, 2000
Actual Primary Completion Date :
Nov 1, 2003
Actual Study Completion Date :
Nov 1, 2003

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No

    DISEASE CHARACTERISTICS: Advanced nonhormone responsive malignancy (metastatic or incurable) Nonvolitional weight loss of between 6-9% of usual body weight over past 6 months OR Decrease of 5 pounds in the past 2 months or less (not greater than 10% loss of usual body weight) No clinical or radiologic evidence of ascites or pleural effusion No lytic bone metastases

    PATIENT CHARACTERISTICS: Age: Over 18 Performance status: ECOG 0-1 Life expectancy: At least 4 months Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Cardiovascular: No venous thrombosis No congestive heart failure Other: Able to participate in exercise program for 1 hour, 3 times/week No physical handicap that precludes aerobic or resistance exercise No clinical abnormality that renders exercise a risk At least 1 month since strength training of 3 hours or more per week No physical or functional obstruction to food intake No uncontrolled emesis greater than 5 episodes/week No diarrhea greater than 4 stools/day intractable to antidiarrheal medication No IV hyperalimentation No contraindications to megestrol No dementia or mental incompetence No known AIDS Not pregnant or nursing Negative pregnancy test

    PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified Endocrine therapy: No concurrent adrenal steroids (other than for replacement), anabolics, appetite stimulants, or progestational agents Intermittent corticosteroids as antiemetic or premedication for cancer treatment allowed At least 6 weeks since prior megestrol Radiotherapy: Not specified Surgery: Not specified

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Arkansas - Department of Geriatrics North Little Rock Arkansas United States 72114-1706
    2 Pacific Shores Medical Group Long Beach California United States 90813
    3 Shands Hospital and Clinics, University of Florida Gainesville Florida United States 32610-100277
    4 Robert H. Lurie Comprehensive Cancer Center, Northwestern University Chicago Illinois United States 60611-3013
    5 Office of David Cella Evanston Illinois United States 60201
    6 Rex Healthcare Raleigh North Carolina United States 27607

    Sponsors and Collaborators

    • Northwestern University
    • National Cancer Institute (NCI)

    Investigators

    • Study Chair: Jamie Hayden Von Roenn, MD, Robert H. Lurie Cancer Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Northwestern University
    ClinicalTrials.gov Identifier:
    NCT00004912
    Other Study ID Numbers:
    • NU FDA98CC6
    • NU-98CC6
    • NCI-G00-1705
    First Posted:
    Mar 3, 2004
    Last Update Posted:
    May 30, 2012
    Last Verified:
    May 1, 2012

    Study Results

    No Results Posted as of May 30, 2012